AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01356017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan 80mg, S-amlodipine 5mg
Description: Telmisartan 80mg and S-amlodipine 5mg, Oral, Once a day, for 9 days + Wash out (19 days)
Study NCT01356017 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan 80mg
Description: Telmisartan 80mg, Oral, Once a day, for 9 days + Wash out (19 days)
Study NCT02223234 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emails and 4 Home Visits
Description: Weekly emails and 4 home visits with health educator
Study NCT02223234 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Monthly emails on child health
Study NCT02223234 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emails and 2 home visits
Description: Weekly emails and 2 home visits with health educator
Study NCT01846130 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Leucine
Study NCT01846130 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Study NCT01846130 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein
Study NCT02931734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Resin modified glass ionomer
Description: Prophylaxis, washing and removing water excess , apply the Clinpro forming a uniform layer of 0.5mm, lightcure for 20 seconds
Study NCT02931734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium Nitrate 2%
Description: Prophylaxis, apply uniformly on the teeth, wait 10 minutes, remove the gel from the teeth with cotton and abundant water.
Study NCT02931734 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low level laser therapy
Description: Prophylaxis, applying infrared laser at low power in points: mesial, buccal, distal and in the apical point in the foyer of fornix with power of 110MW for 11 seconds at each point.
Study NCT00689650 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1540 nm fractional laser
Study NCT01558154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese herbs
Description: Chinese herbs special for depression
Study NCT01558154 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: six acupuncture point including DU20, EX HN3, EX HN1, PC6,HT7,SP6,special for depression
Study NCT01558154 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Thought Imprint Psychotherapy under lower Resistance State
Study NCT01558154 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: Give magnetic stimulation at head
Study NCT00755482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aquamin F
Study NCT00755482 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (maltodextran)
Study NCT02962713 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ART with Equia
Description: Occlusal-proximal ART restorations in primary molars using Equia (Easy/Quick/Unique/ Intelligent/Aesthetic) will be performed. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with GIC (Glass Ionomer Cement). The cavity will be filled with GIC. After the press-finger technique, the excess of material will be removed and occlusion will be checked.
Study NCT02962713 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ART with Giomer Beautifil-Bulk Restorative
Description: Occlusal-proximal ART restorations in primary molars using Giomer will be performed. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with Giomer Beautifil-Bulk Restorative and occlusion will be checked.
Study NCT02137369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Selective serotonin re-uptake inhibitor
Description: Escitalopram, 20mg-40mg daily or Sertraline 50-150 mg daily for 12 weeks
Study NCT02137369 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Cognitive Behavioral Therapy, standardized, 16 sessions over 12 weeks.
Study NCT02137369 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combination treatment (SSRI + CBT)
Description: study participants who do not remit in the first 12 weeks will be offered combination treatment of both treatments for 12 more weeks.
Study NCT01357967 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SSRI monotherapy
Description: SSRI (paxil CR, es-citalopram, fluoxetine, sertraline) start with (paxil CR 12.5mg, es-citalopram 10mg, fluoxetine 20mg, sertraline 50mg) for 1 week up to maximal dosage, flexible dosage, usually in the morning
Study NCT01357967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seroquel XR adjunctive
Description: Quetiapine group:~seroquel XR 50mg Day 1 --> 50mg Day 2 --> 150mg Day 3 --> 150mg Day 4 --> adjustment usually at hs but can be daytime
Study NCT03317600 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Intervention is a nerve block with Lidocaine 2% with Adrenaline.
Study NCT03317600 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intervention is a placebo nerve block with isotonic saline
Study NCT03986853 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood sampling under general anesthesia
Study NCT04388020 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tabletop prototype of eSpecs: Active projection of defocused image in the peripheral visual field
Description: For the right/test eye, a defocused image is projected onto the peripheral retina while the subject views a distant, in-focus image
Study NCT04388020 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tabletop prototype of eSpecs: No Active projection of defocused image in the peripheral visual field
Description: For the left/control eye, no image is projected onto the peripheral retina. The subject views a distant, in-focus image.
Study NCT04616768 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRO questionnaire
Description: These text message surveys will inquire about seven symptoms, requesting a response rating the patient's response. The seven symptoms have been selected by lung and GI oncology clinicians at PCAM from a list of twelve validated symptoms from the National Cancer Institute's Common Terminology Criteria for Adverse Events and will be scored on a five point scale from 0 (no present) to 4 (disabling). The patients will also receive a question asking about their activity level over the prior month
Study NCT04616768 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Step monitoring
Description: A CRC will provide patients with a Fitbit at enrollment and instruct them on how to wear the Fitbit device and periodically sync the device with their phone which will send updated step data to the research team.
Study NCT04616768 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active nudge text feedback
Description: Intervention patients in arm c will receive text feedback describing worsening or severe symptoms collected from their remote PRO questionnaires (i.e. Your following symptoms are severe or have gotten worse:) and their step count (Your Fitbit step count compared to last week is worse.). They will also receive an active nudge question on their upcoming visit (i.e. Do you plan on discussing these symptoms with your oncologist at your upcoming visit? Type 1 if you plan to discuss them; Type 2 if you do not plan to discuss them.).
Study NCT04616768 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PROStep Dashboard (clinicians)
Description: The study team will provide an updated PROStep Dashboard to lung or GI oncology clinicians for each patient enrolled in the intervention arms prior to their appointments. W2H will generate the dashboards and the study team will physically deliver it to their office or touchdown space or send electronically. The Dashboard will include:~1. Home-based PRO report, including the weekly survey results for each question in tabular and graphical form~2. Step data report, including a summary of number of daily steps in graphical form (with rolling weekly averages) and weekly averages in tabular form~3. A list of all acute care utilization in the UPHS system in the prior 6 months including Oncology Evaluation Unit visits, Emergency department visits, Inpatient admissions~4. Whether the patient has had an outpatient palliative care visit~5. Whether the patient has had a documented Serious Illness Conversation
Study NCT03460223 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSC
Description: conventional plus MSC or placebo treatment
Study NCT01702753 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium animalis subsp. lactis
Study NCT03413436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lobaplatin
Description: at least one cycle adjuvant chemotherapy after esophagectomy
Study NCT03413436 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: at least one cycle adjuvant chemotherapy after esophagectomy
Study NCT00778674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets
Study NCT00778674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets
Study NCT04160780 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: L-PRF
Description: sinus augmentation using L-PRf as sole graft material
Study NCT04160780 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: L-PRF mixed with xenograft
Description: sinus augmentation using L-PRF mixed with xenograft as sole graft material
Study NCT04160780 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: xenograft
Description: sinus augmentation using xenograft as sole graft material
Study NCT01237639 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Red blood cell Transfusion
Description: Transfusion of Red blood cells to based on daily complete blood count
Study NCT01237639 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Red blood cell Transfusion
Description: Transfusion of Red blood cells to based on daily complete blood count
Study NCT00058123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: poly ICLC
Study NCT03969654 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PERSONA Total Knee
Description: Primary Total Knee Arthroplasty
Study NCT03969654 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vanguard Total Knee
Description: Primary Total Knee Arthroplasty
Study NCT03969654 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NexGen Total Knee
Description: Primary Total Knee Arthroplasty
Study NCT01771198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIMVASTATIN
Description: SIMVASTATIN tablet of 40mg once a day during 30 days
Study NCT01212770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast 20mg
Description: Apremilast 20 mg twice daily, orally
Study NCT01212770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast 30mg
Description: Apremilast 30 mg twice daily, orally
Study NCT01212770 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03722368 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RCHC
Description: The RCHC group will receive a three hour psychoeducational intervention on common stress responses among healthcare providers and coping skills. They will also receive a booster session one month later which will reinforce these skills.
Study NCT03722368 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RCHC+
Description: The RCHC group will receive a three hour psychoeducational intervention on common stress responses among healthcare providers and coping skills. They will also receive a booster session one month later which will reinforce these skills. This intervention group will also receive on-going support groups and one on one counseling as needed.
Study NCT03722368 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Waitlist control
Description: This group will served as the control group and will receive treatment as usual until the end of the study. At the end of the study they will have the opportunity to take part in the RCHC or RCHC+
Study NCT02483169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cilostazol
Description: Cilostazol 100mg bid
Study NCT02483169 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probucol
Description: Probucol 250mg bid
Study NCT02483169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probucol
Description: Probucol 250mg bid
Study NCT02483169 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 100mg qd
Study NCT02483169 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo of cilostazol
Description: same shape and size of active cilostazol
Study NCT02483169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of aspirin
Description: same size and shape of active aspirin 100mg
Study NCT02483169 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intima-medial thickness
Description: ultrasound measured IMT of both common carotid arteries
Study NCT02483169 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intima-medial thickness
Description: ultrasound measured IMT of both common carotid arteries
Study NCT05214872 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: laboratory parameters - complete blood count
Description: the complete blood count was analyzed using Sysmex K-4500 Automated Hematology Analyzer (by GMI Inc., USA):~* hemoglobin (HGB) \[g/dl\];~* red blood count (RBC) \[10\^12/l\];~* hematocrit (HCT) \[l/l\];~* white blood cells (WBC) \[10\^9/l\];~* platelet count (PLT) \[10\^9/l\]
Study NCT05214872 — intervention group
Intervention type: OTHER
Intervention: body mass index (BMI) [kg/m^2] calculation
Description: body mass index (BMI) \[kg/m\^2\] was calculated by dividing a person's weight (post-HD weight in HD group) \[kg\] by the squared their body height \[m\]
Study NCT05214872 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: selected parameters of oxidative stress (1)
Description: Serum concentration of:~* advanced glycation ends products (AGE) \[µg/mg protein\];~* 3-nitrotyrosine (3-NT) \[µmol/mg protein\];~* advanced oxidation protein products (AOPP) \[µmol/mg protein\];~* carboxymethyle(lysine) (CML) \[µg/mg protein\]~were determined with the enzyme immunoassay methods (ELISA) using Shanghai Sunred Biological Technology Co kits, China.
Study NCT05214872 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: metalloproteinases
Description: metalloproteinases in the serum \[ng/ml\]:~* metalloproteinase 9 (MMP-9) in the serum was determined by the ELISA method using the Quantikine Human MMP-9 (total) kit, by R\&D Systems, Canada;~* tissue inhibitor of metalloproteinase 1 (TIMP-1) in the serum - was determined by the ELISA method using the Quantikine Human TIMP-1 kit, manufactured by R\&D Systems, Canada;~* the MMP-9/TIMP-1 ratio was calculated by the quotient of the MMP-9 and the TIMP-1 concentration.
Study NCT05214872 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: parameters of lipids metabolism in the serum
Description: * total cholesterol (T-C) \[mg/dl\] - was assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA;~* low-density lipoprotein cholesterol (LDL-C) \[mg/dl\] - was assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA;~* high-density lipoprotein cholesterol (HDL-C) \[mg/dl\] - was assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA;~* triglycerides (TG) \[mg/dl\] - were assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA;~* the concentration of low-density lipoprotein (LDL-C) cholesterol - was determined from Friedewalds' equation (LDL-C \[mg/dl\] = total cholesterol (T-C) \[mg/dl\]- HDL-C \[mg/dl\]- TG\[mg/dl\]/5).
Study NCT05214872 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: parameters of iron metabolism
Description: * iron concentration \[mg/dl\] - was analyzed with the Cobas Integra 400 plus biochemical analyzer from Roche Diagnostics, USA;~* total iron-binding capacity (TIBC) \[mg/dl\] - was analyzed with the Cobas Integra 400 plus biochemical analyzer from Roche Diagnostics, USA;~* the unsaturated iron-binding capacity (UIBC) \[mg/dl\] was determined by an equation in which iron concentration in plasma is subtracted from TIBC \[mg/dl\];~* ferritin \[ng/ml\] concentration was determined with the Modular E-170 biochemical analyzer from Roche Diagnostics, USA.
Study NCT05214872 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: selected inflammatory markers
Description: * high-sensitivity C-reactive protein (hsCRP) \[mg/l\] was measured using DADE Behring, USA and the DADE nephelometer Behring Analyzer II;~* neopterin \[nmol/l\] was determined by using the Neopterin ELISA kit, DRG International, Inc., USA;~* interleukin 18 (IL-18) \[pg/ml\] concentration was determined by Colorimetric Sandwich ELISA, Quantikine Human IL-18 R\&D Inc., USA.
Study NCT05214872 — intervention group
Intervention type: DEVICE
Intervention: carotid intima-media thickness (IMT)
Description: carotid intima-media thickness (IMT) \[mm\] was measured by The Accuson CV 70 system (Siemens) with a 10 megahertz (Mhz) transducer.~Two longitudinal projections were assessed (anterolateral and posterolateral). The distal 1 cm of the common carotid artery just proximal to the bulb was measured by means of a computer analysis system (Medical Imaging Applications, LLC).
Study NCT05214872 — intervention group
Intervention type: DEVICE
Intervention: non-invasive cardiological examinations
Description: For non-invasive cardiological examinations, the Portapres device (Finapres Medical Systems (FMS), the Netherlands), the SphygmoCor tonometer (AtCor Medical), the Colin blood pressure monitor (BMP)-7000 (Japan) were used.~Main assessed variables: heart rate (HR) \[beats per minute \[bpm\]\]; ejection duration (ED) \[millisecons\]; peripheral systolic (pSBP) and diastolic blood pressure (pDBP) \[mm Hg\]; peripheral mean arterial pressure (pMAP) \[mm Hg\]; peripheral end-systolic pressure (pESP) \[mm Hg\]; central systolic (cSBP) and diastolic blood pressure (cDBP) \[mm Hg\]; central mean arterial pressure (cMAP) \[mm Hg\]; central augmented pressure (cAP) \[mmHg\]; central mean pressure of diastole (cMPD)\[mm Hg\]; central mean pressure of systole (cMPS) \[mm Hg\]; central end-systolic pressure (cESP) \[mm Hg\].
Study NCT05214872 — intervention group
Intervention type: DEVICE
Intervention: vessel stiffness assessment
Description: The following parameters of vessel stiffness were assessed by Pulse Trace 2000 (Micro Medical Ltd., Rochester, Kent, United Kingdom):~* reflection index (RI) \[in percentages \[%\]\];~* vascular stiffness index (SI) \[m/s\];~* peripheral pulse pressure (pPP) \[mm Hg\];~* central puls pressure (cPP) \[mm Hg\]~* peripheral pulse pressure/central pulse pressure (pPP/cPP ratio).
Study NCT05214872 — intervention group
Intervention type: OTHER
Intervention: cardiovascular (CV)-related death recording during 2-year follow-up
Description: During a 2-year follow-up from the enrollment to this study, CV-related fatal incidents history has been recorded for each subject separately. The primary endpoint was fatal acute myocardial infarction (AMI) or acute ischemic stroke or any unexpected or sudden death only if autopsy proved CV-related. If there was doubt about the cause of death or there was no contact with the patient during the two years from study enrollment, that patient was excluded and not considered further.
Study NCT05214872 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: glucose (Glu)
Description: glucose (Glu) \[mg/dl\] was assessed in the serum by a routine technique using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA.
Study NCT05214872 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: klotho
Description: klotho \[ng/ml\] - was analyzed in the serum by Human KL(Klotho) \[ng/ml\] ELISA Kit, Shanghai Sunred Biological Technology Co kit, China.
Study NCT03143985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: POM, an analog of thalidomide, is an immunomodulatory agent with antineoplastic activity. Myeloma tumor cells exposed to POM, undergo growth arrest and increased apoptotic cell death. POM enhances T cell- and natural killer cell-mediated immunity and inhibit production of pro-inflammatory cytokines by monocytes. POM may be taken orally with water. Capsules should not be broken, chewed or opened. POM should be taken without food (at least 2 hours before or 2 hours after a meal). POM will be commercially available. POM will be taken by mouth at a dose of 4mg per day
Study NCT00740792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azelastine HCl/fluticasone propionate
Description: azelastine HCl 548 mcg/ fluticasone propionate 200 mcg one spray per nostril BID
Study NCT00740792 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azelastine Hcl
Description: azelastine Hcl 548 mcg one spray per nostril BID
Study NCT05214872 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: fibroblast growth factor 23 (FGF-23)
Description: FGF-23 \[pg/ml\] - was analyzed in rhe serum using Human FGF-23 ELISA Kit, Sigma-Aldrich, USA.
Study NCT05214872 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: parameters of calcium and phosphate metabolism
Description: * total and ionized calcium \[mg/dl\],~* phosphate \[mg/dl\],~* intact parathormone (iPTH) \[mg/dl\]~were assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA.